Idorsia Ltd (CH:IDIA)
:IDIA
IDIA Stock Chart & Stats
CHF3.51
-CHF0.05(-3.98%)
At close: 4:00 PM EST
CHF3.51
-CHF0.05(-3.98%)
Day’s Range― - ―
52-Week RangeCHF0.85 - CHF4.85
Previous CloseN/A
Volume178.76K
Average Volume (3M)2.48M
Market Cap
CHF883.71M
Enterprise ValueCHF1.88B
Total Cash (Recent Filing)CHF87.24M
Total Debt (Recent Filing)CHF1.27B
Price to Earnings (P/E)―
Beta1.95
Next Earnings
Apr 28, 2026EPS Estimate
-0.19Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.27
Shares Outstanding252,461,100
10 Day Avg. Volume2,649,008
30 Day Avg. Volume2,478,790
Financial Highlights & Ratios
PEG Ratio0.13
Price to Book (P/B)-0.80
Price to Sales (P/S)4.14
P/FCF Ratio-5.48
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
CHF4.75Price Target Upside35.33% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.55
Revenue Forecast (FY)CHF226.37M
Bulls Say, Bears Say
Bulls Say
Commercial Partnerships And Regional ExpansionExclusive licensing and distribution agreements in Latin America and the Middle East broaden geographic reach and are expected to generate milestone payments, supply revenue, and royalties that can strengthen near-term cash flow.
Leadership And Strategic DirectionReturn of experienced leadership combined with planned independent board additions signals a strategic shift toward prioritizing revenue growth and enhancing execution of commercialization plans.
Pediatric Indication ExpansionPhase 2 pediatric data showed dose-dependent increases in total sleep time with favorable safety down to age ten, supporting potential expansion of the drug into a pediatric insomnia indication for children with neurodevelopmental disorders.
Bears Say
Guidance Visibility And Financial RiskDeclining guidance visibility and higher operating expenses have prompted analysts to lower price targets, reflecting increased downside risk to near-term valuation.
North American Commercialization RiskCommercialization of aprocitentan in North America lacks a confirmed partner and an unclear timeline for a deal creates material execution risk to capturing the drug's projected commercial value.
Regulatory And Clinical Trial RiskRegulatory approval for lucerastat hinges on proving meaningful kidney improvement in pivotal studies, making late-stage trial outcomes a significant execution risk for the asset.
IDIA FAQ
What was Idorsia Ltd’s price range in the past 12 months?
Idorsia Ltd lowest stock price was CHF0.85 and its highest was CHF4.85 in the past 12 months.
What is Idorsia Ltd’s market cap?
Idorsia Ltd’s market cap is CHF883.71M.
When is Idorsia Ltd’s upcoming earnings report date?
Idorsia Ltd’s upcoming earnings report date is Apr 28, 2026 which is in 22 days.
How were Idorsia Ltd’s earnings last quarter?
Idorsia Ltd released its earnings results on Feb 26, 2026. The company reported -CHF0.27 earnings per share for the quarter, missing the consensus estimate of -CHF0.195 by -CHF0.075.
Is Idorsia Ltd overvalued?
According to Wall Street analysts Idorsia Ltd’s price is currently Undervalued.
Does Idorsia Ltd pay dividends?
Idorsia Ltd pays a Notavailable dividend of CHF11.841 which represents an annual dividend yield of N/A. See more information on Idorsia Ltd dividends here
What is Idorsia Ltd’s EPS estimate?
Idorsia Ltd’s EPS estimate is -0.19.
How many shares outstanding does Idorsia Ltd have?
Idorsia Ltd has 252,461,100 shares outstanding.
What happened to Idorsia Ltd’s price movement after its last earnings report?
Idorsia Ltd reported an EPS of -CHF0.27 in its last earnings report, missing expectations of -CHF0.195. Following the earnings report the stock price went up 5.333%.
Which hedge fund is a major shareholder of Idorsia Ltd?
Currently, no hedge funds are holding shares in CH:IDIA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Idorsia Ltd
Idorsia Ltd, a biopharmaceutical company, discovers, develops, and commercializes drugs for unmet medical needs in Switzerland. The company has a clinical development pipeline that cover various therapeutic areas, including CNS, cardiovascular, and immunological disorders, as well as orphan diseases. Idorsia Ltd has a collaboration agreement with Janssen Biotech Inc. to jointly develop and commercialize aprocitentan and its derivative compounds or products; license agreement with Mochida Pharmaceutical for the supply, co-development, and comarketing of daridorexant; and Hoffman-La Roche Inc. to develop and market compounds in the field of cancer immunotherapy. It also has a collaboration with Antares Pharma, Inc. for the development of a self- administered drug device product for Selatogrel; and Neurocrine Biosciences, Inc. to develop and commercialize ACT-709478, which is in Phase II clinical trial for the treatment of epilepsy. The company was incorporated in 2017 and is headquartered in Allschwil, Switzerland.
IDIA Stock 12 Month Forecast
Average Price Target
CHF4.75
▲(35.33% Upside)
Technical Analysis
Molecular Partners AG
―
Basilea Pharmaceutica
―
Kuros Biosciences
―
Newron Pharmaceuticals SpA
―
Santhera Pharmaceuticals Holding
―
Options Prices
Currently, No data available
---